Highlights VALBIOTIS

Equities

ALVAL

FR0013254851

Market Closed - Euronext Paris Other stock markets 11:35:07 2024-05-03 am EDT			5-day change	1st Jan Change
4.13 ^EUR	+0.49%		+5.90%	-17.40%

Apr. 26	Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 03	Valbiotis: launch of Valbiotis PRO Cholesterol in May	CF

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 26	CI
Valbiotis: launch of Valbiotis PRO Cholesterol in May	Apr. 03	CF
Valbiotis: capital increase successfully completed	Dec. 22	CF
Valbiotis: 15 ME capital increase	Dec. 12	CF
Valbiotis SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
Valbiotis SA Presents the Full Results of the Phase II/III REVERSE-IT Study: Impressive Efficacy of TOTUM 63 Against Prediabetes and the Early Stages of Type 2 Diabetes, a First for a Non-drug Active Substance	23-09-11	CI
Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM-63	23-05-22	CI
Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
Valbiotis SA Announces the Last Visit of the Last Patient in the Phase II/III REVERSE-IT Study on TOTUM•63, in Partnership with Nestlé Health Science	23-03-13	CI
Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM--854 Clinical Study, Against High Blood Pressure	23-01-30	CI
Valbiotis SA Announces the Signature of a Research Partnership in Intestinal Microbiota With the MEDIS Unit From the Clermont Auvergne University	22-12-14	CI
Valbiotis SA Presents Additional Positive Results from the HEART Clinical Study on TOTUM•070 for Hypercholesterolemia	22-10-03	CI
Valbiotis SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-15	CI
Valbiotis Announces Completion of Recruitment for the Phase Ii/Iii Reverse-It Clinical Study with Totum•63 Against Prediabetes, in Partnership with Nestlé Health Science	22-07-28	CI
Valbiotis Announces the Major Success of the Phase II Heart Clinical Study the Patented Plant-Based Active Substance Totum•070 Proves Its Efficacy Against Hypercholesterolemia, A Cardiovascular Risk Factor	22-06-13	CI
Valbiotis Announces First Visit of the First Patient in the TOTUM•63 Mode of Action Clinical Study Conducted by the INAF, in Partnership With Nestlé Health Science	22-04-28	CI
Valbiotis SA Announces the Positive Results of Its Clinical Study on the Bioavailability and Mode of Action of TOTUM•070, Against Hypercholesterolemia	22-03-29	CI
Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-15	CI
Valbiotis Announces Approval to Launch the Two Phase II/III Insight and Insight 2 Clinical Studies, the Last Step in the Development of Totum•854 for the Reduction of Blood Pressure	22-02-17	CI
Global markets live: Merck, Volkswagen, Salesforce, Roche, Mondelez...	21-12-01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights VALBIOTIS

Equities

ALVAL

FR0013254851

Highlights

Filters